What did @taylorreidcoachin actually say?
The creator recommended combining BPC-157 (which they called "BBC") and TB-500 ("TV 500") into a dropper and applying the solution directly into the eye. They claimed BPC-157 provides "nerve protection," improves blood circulation, and supports the optic nerve, while TB-500 helps with "crea health" (corneal health), reduces inflammation, and supports tear production. This is not a subtle optimization tip. This is a recommendation to put unsterile, unregulated peptide solutions directly onto one of the most sensitive and infection-prone surfaces of the human body.
To be clear: the creator is not describing an oral or injectable peptide protocol. They are describing ocular self-administration of compounded peptides with no clinical trial data, no established sterility standards for this route, and no regulatory approval for ophthalmic use.
Does the science back this up?
There is legitimate preclinical interest in both peptides for tissue repair, but almost none of it involves ophthalmic application, and none of it supports DIY eye drops. The leap from animal studies to "put this in your eye at home" is enormous and unjustified by the current evidence base.
BPC-157 has shown neuroprotective and angiogenic effects in rodent models. A 2021 review by Sikiric et al. in Current Pharmaceutical Design summarized its effects on wound healing and vascular function, primarily in gut and musculoskeletal contexts. There is one small thread of research on BPC-157 and retinal or optic nerve tissue, but it is limited to animal models and has not been replicated in human ocular studies. TB-500, the synthetic fragment of Thymosin Beta-4, has some corneal data behind it. A 2010 study by Sosne et al. in Investigative Ophthalmology and Visual Science found Thymosin Beta-4 promoted corneal wound healing in mice. That is genuinely interesting. But "interesting animal data" and "safe to self-administer as DIY eye drops" are entirely different categories of claim.
What did they get wrong (or right)?
The corneal healing angle for TB-500 is the one place the creator is not completely off-base. The underlying biology is real. Sosne's work and subsequent research do support a role for Thymosin Beta-4 in corneal epithelial repair. That part gets partial credit.
Everything else is a problem. The BPC-157 optic nerve claim is speculative at best. There is no peer-reviewed human study linking BPC-157 administration to optic nerve protection in any route, let alone ocular drops. The "blood circulation" and "deepening certain parts of the eye" language is vague enough to be meaningless clinically. Tear production support from TB-500 has some biological plausibility through its anti-inflammatory mechanisms, but this has not been studied as a standalone effect in human dry eye disease.
The most serious error is not a factual one. It is the omission of risk. Ophthalmic preparations require sterility standards that compounded peptides from typical research-grade suppliers do not meet. Endotoxin contamination, improper pH, osmolality mismatches, and particulate matter can cause corneal damage, uveitis, or infection. Recommending this route to a lay audience without a single word about these risks is genuinely irresponsible.
What should you actually know?
If you are curious about peptides and eye health, the honest answer is that the science is early, the evidence is mostly animal-based, and no compounded peptide product is currently FDA-approved for ophthalmic use. Thymosin Beta-4 has been studied in formal clinical settings for dry eye and corneal injury, including work by RXi Pharmaceuticals on RGN-259, a pharmaceutical-grade formulation. That is a very different thing from a peptide dropper mixed at home or sourced from a research chemical supplier.
The eyes are not a forgiving site for experimentation. Infections like Pseudomonas aeruginosa keratitis can cause permanent vision loss within 24 to 48 hours. Any legitimate ophthalmologist will tell you that nothing goes in the eye that has not been formulated to USP sterile ophthalmic standards. If you are working with a licensed provider on peptide therapy for recovery or longevity, ask them specifically about the preparation standards for any ocular application. If they cannot answer that question in detail, that is your answer.
The bottom line
The creator is drawing on real peptide biology but applying it in a way that has no clinical validation and carries real safety risk. Partial credit for the TB-500 corneal biology. No credit for the optic nerve claims. Serious concern about recommending ocular self-administration to nearly 10,000 viewers without a single safety caveat.